

ASX ANNOUNCEMENT

28 September 2022

TGA advertising infringement notices



Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") advises it has received infringement notices from the Therapeutic Goods Administration ("TGA") concerning the alleged unlawful advertising of LGP's medicinal cannabis products on its website and certain social media channels, and in particular the contravention of section 42DLB(1) and related subsections of the *Therapeutic Goods Act 1989*.

LGP believes the infringement notices were issued as part of a wider compliance campaign by the TGA focusing on medicinal cannabis companies in Australia, with another two significant Australian cannabis sponsors also receiving infringement notices for contraventions of advertising laws.

LGP expects the infringement notices issued by the TGA will lead to greater compliance throughout the medicinal cannabis industry in Australia with the TGA requirement that unregistered medicines be advertised exclusively to health professionals as long as those advertisements are not accessible to the public.

The TGA has issued the Company with twenty-eight infringement notices, each for a value of \$13,320, as set out below:

- nine infringement notices relating to one page on the LGP website which referenced cannabis and also provided eight links to replacement CMI's (being the Consumer Medicines Information leaflet that contains information on the safe and effective use of a particular medicine) with the name of the product within the link
- ten infringement notices for replicating the SAS B data and conditions from the TGA website and then hash-tagging those medical indications (e.g. #[indication]) and referencing a further medical indication on two social media posts
- seven infringement notices concerning references to cannabis or cannabis medicines on two social media posts

- two infringement notices for social media posts by patients naming LGP medicinal cannabis products on one social media platform.

The total penalty amount of the infringement notices is \$372,960.

The infringement notices were issued after recent consultations between the TGA and LGP concerning the Company's website and social media channels, following which LGP immediately removed the relevant content. All rectification measures have now been undertaken by LGP in respect of the matters raised by the TGA. Given the nature and value of the penalty, LGP will review its options and is considering an appeal.

LGP is undertaking an extensive review of all of its communications materials and practices to ensure strict adherence with TGA and other regulatory requirements moving forward.

ENDS
BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren", written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp